Progenics Pharma (Nasdaq: PGNX) presented positive data from a pivotal phase 2 clinical study of Azedra in an oral presentation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE